2nd Real-World Evidence World Congress 2023 Europe.

9th RWE, Market Access, Pricing & Reimbursement Global Congress 2023 Europe

Copthorne Tara Hotel London Kensington, London, UK

Thursday 4th - Friday 5th May 2023

KEY INDUSTRY EXPERT SPEAKERS

Riad Dirani

VP, Global HEOR, Medical Operations & Excellence

Teva

Riad Dirani

VP, Global HEOR, Medical Operations & Excellence

Riad Dirani, PhD, is currently the VP of Global Health Economic and Outcomes Research and Medical Operations & Excellence at Teva Pharmaceuticals. His responsibilities include overseeing the HEOR, Epidemiology, RWE, Medical Operations, and Medical Communications within Medical Affairs/R&D, and developing and expanding their strategic capabilities optimize the development and commercialization of Teva’s portfolio of products and offerings globally in innovative, generic, and biosimilar medicines. Riad has worked in the pharmaceutical industry since 2000, including positions of increasing responsibility at Aventis, GlaxoSmithKline, Pfizer, and Johnson & Johnson in multiple therapeutic areas. Riad joined Teva in 2014 to build the HEOR group and establish its operating model. Riad received his Ph.D. in Health Services Research/Health Economics from The Pennsylvania State University.

Stephane Read

Senior Technical Consultant in Epidemiology

Certara Evidence & Access

Stephane Read

Senior Technical Consultant in Epidemiology

Stephane Read is a senior technical consultant in epidemiology at Certara Evidence & Access. Prior to joining the team in 2020, she obtained her Master of Public Health and PhD in biostatistics and epidemiology from the University of Edinburgh. In addition, she has completed two post-doctoral fellowships at the University of Edinburgh and Women’s College Hospital (Canada). She has over eight years of experience in using real-world data (claims, electronic healthcare records, chart review) to conducting a wide range of studies including burden of illness, external control arm and comparative effectiveness studies.

Rafael Souza

Head of Access Solutions & Pricing, New Markets

BeiGene

Rafael Souza

Head of Access Solutions & Pricing, New Markets

14+ years of experience on Diagnostics and Pharma companies driven by customer needs and market trends. Experience in Science, Sales, Marketing and Access (Pricing, Policy, Evidence, HTA and Strategy) with strengths in Oncology, Immunology, Neuroscience, Rare Diseases, Hemotherapy, Hemophilia and Infectious Disease on Private and Public payer system in Latin America, Middle East, Africa, Europe and Global level.

MARCO RAULAND

Vice President Global Market Access & Pricing - Strategic Planning

Merck KGaA

MARCO RAULAND

Vice President Global Market Access & Pricing - Strategic Planning

Marco Rauland has more than 20 years of drug development, marketing, market research and pricing consulting experience in the pharmaceutical industry. Prior to joining Merck, Marco was Vice President Europe of GfKs Market Access practice. Before that Marco was the global head of the pricing, access and reimbursement practice of Genactis and Senior director of the pricing and reimbursement business unit at TNS Healthcare (now Kantar Group). Marco is an expert in global pricing, listing and reimbursement strategy and has extensive experience in implementing pricing, access and reimbursement solutions at all stages of the product life cycle, from early product development to post-launch pricing strategies. He has developed the pricing, access and reimbursement strategy for product launches across numerous therapy areas and has in-depth knowledge of international country pricing & reimbursement systems. Marco studied Biochemistry and Pharmacology at the University of Cologne and holds a PhD in Natural Science.

DANIEL JACKSON

Global Head - Market Access Policy

UCB

DANIEL JACKSON

Global Head - Market Access Policy

Dr Jackson is an experienced pharmaceutical access professional and is the Global Head of Market Access Policy at UCB. With over 20 years of access experience in the healthcare sector, leading market entry strategies, securing pricing optimization and delivering economic differentiation through strategic pricing, HE&OR, and health policy initiatives.

ANA PLATA

Global Pricing Head - BioPharmaceuticals

AstraZeneca

ANA PLATA

Global Pricing Head - BioPharmaceuticals

Ana Plata is a healthcare strategy leader with 10+ years of pricing & market access experience, with roles of increasing responsibility across pharmaceuticals’ lifecycle: from early pipeline to launch leadership, in both a strategic and operational capacity. Currently, Ana is the Global Pricing Head at AstraZeneca Biopharmaceuticals, where she is responsible for the development and implementation of pricing policies across the portfolio lifecycle, from launch readiness to loss of exclusivity management. Prior to AstraZeneca, Ana held different access leadership roles at UCB, including leading the Global Pricing team responsible for the pricing strategy & pricing operations across the company portfolio, and the New Medicines Patient Access Team responsible for access strategy for the early portfolio and Business Development. Ana joined UCB from Novartis, where she led the development and implementation of the global pricing and access strategy for the launch of Entresto® in heart failure. Prior to Novartis, Ana worked as an access strategy consultant at IMS (now IQVIA), with projects across multiple geographies and therapy areas. Ana holds a PhD in Bioengineering from Imperial College London and a MEng in Aeronautical Engineering from Universidad Politecnica de Madrid. Ana is passionate about increasing access to innovative medicines globally, especially in currently underserved low & middle-income countries

CLAUDIA NEUBER

Head, Global Pricing Oncology, Global Market Access & Pricing

AstraZeneca

CLAUDIA NEUBER

Head, Global Pricing Oncology, Global Market Access & Pricing

CLAUDIA NEUBER has been Head of Global Pricing Implementation at AstraZeneca PLC since January 2016 and moved to the newly role of Head of Oncology in fall of 2021. Prior to this role she worked as the Director of Pricing and Contracting at AstraZeneca Canada, in addition she served as vice-chair of the industry pricing committee and served as an industry representative in numerous government consultations. She has over 30 years of industry experience. During this time she has worked in a variety of roles in the areas of Sales, Marketing, Strategic Planning/Finance, Knowledge Management, and Pricing/Access functions. She holds a Bachelor of Science from the University of Toronto and an MBA from the Schulich School of Business. She currently lives in the UK with her husband and two children.

SILVY MARDIGUIAN

Market Access Director, UK & Ireland

BeiGene UK

SILVY MARDIGUIAN

Market Access Director, UK & Ireland

Silvy has a PhD in pharmacology with 12 years of experience in market access and HEOR, developing global, regional, and country-specific market access strategies, assessing commercial opportunities and conducting landscape assessments, developing Global Value Dossiers and HTA dossiers, evidence generation plans, negotiation guides and other strategic documents to ensure optimal reimbursement of pharmaceuticals and patient access globally - Worked across all the major therapy areas, with particular experience in oncology, rare diseases, immunology, cardiovascular diseases, neurological diseases, and vaccines

ELVIRA MÜLLER

Vice President

Certara Evidence & Access

ELVIRA MÜLLER

Vice President

Elvira Müller is a Vice President at Certara Evidence & Access, responsible for HTA and Evidence Development as well as managing the EvA market access and analytics consulting team based in Germany. She oversees the strategic, scientific, and operational performance with focus on reimbursement strategy and submissions, health technology assessments (HTA) as well as evidence synthesis. Elvira is a specialist in Early engagements with HTA bodies for early dialogues/scientific advice and has substantial expertise in joint European activities through EUnetHTA collaboration (early dialogues, joint assessments, core HTA). For German market needs, she and her team focus on strategy consulting, dossier development and analytics tailored to AMNOG requirements. Elvira looks back on 20 years of experience in global market access following her graduation in natural sciences (MSc, PhD) and public health (MPH).

RYOTARO ISHIKAWA

Global Market Access Director

Novartis

RYOTARO ISHIKAWA

Global Market Access Director

Ryotaro joined Novartis in 2006 as Brand Manager for Transplantation & Infectious disease in Latin America and rapidly went on to hold several positions of increasing responsibility within the CPO, notably as Specialty Franchise Head and Market Access Head. He then became Regional Pricing & Access Director for the LACan Region, and subsequently moved to Basel to work as Global Market Access Director, Respiratory, currently is the Gene Therapies Head of Access for central European cluster in Novartis. Before joining Novartis, Ryotaro practiced medicine, worked as a payor, to later move into sales in medical devices and renal therapy services. Moreover, he also served in the military with the Multinational Force and Observers - UN, an international peacekeeping force based in the Sinai peninsula. He is an MD, holds both a degree in Hospital Administration and a Master in Business Administration from Universidad de los Andes in Colombia, as well as a postgraduate diploma in Intellectual Property. He has an extensive and unique experience in Commercial, Access, healthcare systems and payor environments,

MARIA DANCHENKO

Global Market Access Academy Lead

Sanofi

MARIA DANCHENKO

Global Market Access Academy Lead

Over 15 years with Sanofi, currently leading the Global Market Access Academy. Focusing on developing the strategic capability building and collaborative problem solving for market access colleagues and market access knowledge building of our functional partners. A seasoned market access professional with almost 15 years of experience in the market access arena. Most recently served as Market Access Lead for AMEE and International regions, responsible for the development and execution of regional market access strategies for Sanofi mature portfolio as well as new launches. Worked previously in the Global Pricing Team, being responsible for the global pricing strategy of several brands over product lifecycle including peri-LOE, specializing in the IRP impact assessment. Started her career in Market Access Department of the Russian affiliate as Eurasia Pricing Manager. Before her market access experience, Maria worked in several roles and companies within the medical and marketing functions. Has a degree in Foreign languages from Yaroslavl State Pedagogical University (Yaroslavl, Russia) and a degree in PR & Advertising from Moscow (Lomonosov) State University as well as a European Market Access University Diploma (EMAUD) received from Lyon 1 University (France).

LAURA A CLARK-KELLY

Sr. Director

Bayer Pharmaceuticals

LAURA A CLARK-KELLY

Sr. Director

Laura Clark-Kelly has worked with the pharmaceutical industry, health plans, and pharmacy benefit management organizations (PBMs) to enhance their communication, connection, and confidence so that they can have a significant impact on physicians and patients. Her guiding principle has been that people should be able to get the medicines they need at prices they can afford. This passion has led her leadership vision to new heights. Laura has over twenty years of broad base business experience, a knack for making meaningful connections, an insatiable appetite for learning, along with a dedication to assisting others in maximizing their potential. Laura has a deep interest in people, leadership, and making a positive difference in the world. She finds particular motivation in empowering others to achieve personal and professional breakthroughs. She discovered that volunteering was one way she could give back. When she is not ensuring profitable market access for pharmaceutical products, Laura can be found preparing delectable meals, reading beach novels (even in the winter), and spending time with her family, which includes her labradoodle, Henry.

MAARTEN VAN BAELEN

Executive Director

Plasma Protein Therapeutics Association

MAARTEN VAN BAELEN

Executive Director

Maarten is the Executive Director of the Plasma Protein Therapeutics Association (PPTA). The PPTA is a dynamic trade association that represents a unique sector of the biologics and biotechnology industry. PPTA represents more than 1.100 human plasma collection centers in North America and Europe, as well as, the manufacturers of lifesaving plasma-derived medicines. PPTA’s mission is, as a trusted partner to health systems, to drive broad and reliable access to plasma protein therapies, with a focus on the well-being of patients and plasma donors. Prior to joining PPTA in 2019, Maarten worked as Market Access Director and Medical Affairs Manager at Medicines for Europe, the trade association representing the European generic, biosimilar and valued added pharmaceutical industries. In addition, during that time, Maarten was advisor to the Board of the European Medicines Verification Organization (EMVO). After graduating as a pharmacist from KU Leuven, Maarten spent several years working in medical affairs roles in the pharmaceutical and medical devices industry, while also being a practicing pharmacist. Maarten also obtained an MBA from the Solvay Brussels School Economics & Management and the École des Ponts Business School in Paris

VASILIKI PATSIOURA

Global Pricing Implementation Lead

Astrazeneca

VASILIKI PATSIOURA

Global Pricing Implementation Lead

Vasiliki Patsioura- Global Pricing Implementation Lead at Astrazeneca (MSc Health Economics, Policy and Management, LSE) With more than 10 years of professional experience in pharmaceutical consulting and industry access roles; a health economist by training served as part of the technical team for guidelines development at the National Guidelines Centre (part of NICE); Her interests are around pharmaceutical pricing both strategical and operational and how these can enable access to innovative therapies for patients

SANTOKE NAAL

Director Market Access

IGES U.K. Pharma Ltd

SANTOKE NAAL

Director Market Access

Santoke Naal studied Biochemistry at the University of Leeds, UK and holds a Diploma in Company direction from the Institute of Directors. With over 30 years experience working in the pharmaceutical field with companies like BMS, Pfizer and Novartis in various leadership positions. Involved in leading the market access division for IQVIA. Prior to joining IGES UK Pharma, Santoke was the Commercial Director for the ABPI working with Government bodies on access and uptake for medicines in the UK.

MATTHIAS HECK

Attorney-at-law, Senior Director, International TA Policy Strategy

Alexion AstraZeneca Rare Disease

MATTHIAS HECK

Attorney-at-law, Senior Director, International TA Policy Strategy

Matthias combines market access expertise from practical experience from funding negotiations across diverse EU markets, including AMNOG, as well as from leading engagement on framework conditions from a policy perspective at national and European levels. Next to company experience, Matthias’ experience includes serving as Head of Brussels office of the German Pharmaceutical Industry Association as well as Legal Counsel of the European Confederation of Pharmaceutical Entrepreneurs (EUCOPE). He has regularly written and spoken on life sciences topics. Matthias is a fully qualified lawyer (Cologne Bar) and holds a Masters in International Economic Relations and Diplomacy (Budapest / St. Gallen).

MITUN PATEL

Director

Red Nucleus

MITUN PATEL

Director

Mitun joined Red Nucleus in Q1 2023. He has over a decade of experience in global pricing, market access and value strategy across Europe and emerging markets. Most recently he has spent 3 years as Director / Head of Market Access at pediatric orphan drugs manufacturer Diurnal, and generics manufacturer EQL Pharma. Prior to this Mitun has held roles at an eclectic selection of consultancies, honing his experience in commercial strategy within the pharmaceutical industry. Mitun holds a first-class honors degree in Biological Sciences from Imperial College London as well as an MSc in International Health Management from Imperial College Business School. He is based out of the London office but currently lives in Reading.

HIGIA VASSOLER

Associate Director

Red Nucleus

HIGIA VASSOLER

Associate Director

Higia has a combination of consulting, business intelligence and forecasting experience in the pharmaceutical industry. Over the past several years in P&MA consulting, Higia has gained a comprehensive perspective on global pricing and reimbursement, market access, value strategy, and evidence generation strategy. She has worked with both small to mid-sized companies and several of the 20 largest biopharmaceutical firms on engagements spanning the US, EU5, and less traditional markets. Higia has a diverse therapeutic area knowledge set including oncology, haemophilia, dermatology and a wide range of rare diseases. Higia holds a PGCert in Health Economics from the University of York and an MSc In Drug Discovery from UCL, and is based in London.

JOSIE GODFREY

Co-Founder and CEO, Realise Advocacy, Director

JG Zebra Consulting

JOSIE GODFREY

Co-Founder and CEO, Realise Advocacy, Director

Josie is the Director of JG Zebra Consulting which provides independent consultancy services with a focus on rare diseases and innovative technologies. She is Co-founder and CEO of Realise Advocacy which supports patient advocacy groups to maximise their impact in HTA and access. Her current projects include providing strategic market access, policy and stakeholder engagement advice, and support to pharmaceutical companies, trade bodies, and patient advocacy groups. She is the Strategic Director for Duchenne UK’s Project HERCULES, an award-winning international multi-stakeholder collaboration developing evidence and tools to support Health Technology Assessments (HTAs) for new treatments for Duchenne Muscular Dystrophy. Josie has extensive experience in rare diseases and led the establishment of the Highly Specialised Technologies programme at NICE, the National Institute for Health and Care Excellence in the UK which carries out Health Technology Assessments of treatments for very rare diseases.

ESTHER NZENZA

Founder and CEO

Decisive Consulting Ltd.

ESTHER NZENZA

Founder and CEO

Esther Nzenza is a seasoned pharmaceutical executive with over 24 years of experience across domestic, regional and international leadership roles. Esther has built and led teams supporting all Commercial Capabilities at an International level, in both Speciality and Rare disease. As the Founder and CEO of Decisive Consulting, Esther specialises in providing the capacity and capability to enable and empower companies at “decisive moments” of their evolution, with a particular focus on Market Access, Capability Development and Commercial Strategy. Blending technical understanding, lived experience and a global network of trusted advisers, Esther and her team can accelerate and focus plans for International commercialisation.

FRANKIE SHUPO

Global Director, Market Access and HEOR

EUSA Pharma

FRANKIE SHUPO

Global Director, Market Access and HEOR

Frankie is a well-experienced, values-driven Health Economist with expertise in all areas of HEOR methodologies and Market Access in the global market. For nearly two decades, Frankie has employed his knowledge and skills to support pharmaceutical product development and their commercialisation of compounds at all stages of their development in multiple therapeutic areas and for Pharma businesses of different sizes. Frankie has a strong track record of delivering outstanding project outcomes matched by his successes in global HTA submission successes and reimbursement, and publication of his HEOR work in both congresses and peer-reviewed journals. Frankie currently holds the position of Global Market Access and HEOR Director at Recordati where he has been employed for the last three years.

OMAR ALI

Visiting Lecturer Value Based Pricing & Innovative Contracting of New Medicines

University of Portsmouth

OMAR ALI

Visiting Lecturer Value Based Pricing & Innovative Contracting of New Medicines

An enthusiastic and well experienced pharmacist with over 20 years comprehensive experience as an NHS Pharmacy Payer [NHS CCGs & Acute Hospitals]. He is confident and innovative, using a well-balanced mastery of skills to achieve goals, maximise potential and bring about shared vision on future landscape for pricing and reimbursement of health technologies. Bridging the gap between payer’s unmet needs and commercial pharma value propositions is his passion. With 9 years experience as an adviser to NICE and a newly appointed role as Visiting Lecturer in Value Based Pricing & Innovative Contracting at the University of Portsmouth, he is well placed to bring expert strategic insights along with access to a powerful National/International Network of Payers within the EU5 managed markets. He has lectured world wide, and recently undertaken PhD doctorate, the thesis entitled “Value Based Pricing & Outcomes Based Innovative Contracting of Medicines”.

MENI STYLIADOU

VP Global Program Leader – Health Data Partnerships, Data Science Institute.

Takeda R&D

MENI STYLIADOU

VP Global Program Leader – Health Data Partnerships, Data Science Institute.

Meni is leading a Takeda Global Program to build sustainable health data partnerships to unleash the power of data and digital in the benefit of patients, science and society. Meni is also the Founder and Project Leader of the H2O, a public private partnership among 23 organisations funded through the Innovative Medicines Initiative (IMI). The goal of the H2O is equip patients with digital tools to monitor their outcomes in a standardised manner while being in control of their data. Meni joined Takeda on the 1st of October 2015 as VP Public Policy and Government Affairs for Europe & Canada (EUCAN). Her focus has been to help Takeda take advantage of public policy trends and create win- win business models for society and the company. In this context, Meni has been pioneering the creation of partnerships between the healthcare industry, healthcare providers and public sector to leverage digital technologies in order to create transparency of health outcomes and improve efficiencies in healthcare. Prior to joining Takeda, Meni worked for 9 years for Novartis in several roles in public policy and ethical leadership. Prior to that, Meni held a number of international positions in both the public and private sectors focusing on how to accelerate broadband in Europe and how to create a public policy environment that would allow Europe to enter successfully into the digital era. Meni started her career in the European Commission in 1991 as a legal expert focusing on telecom law and policy. She studied law in Greece and Belgium and she specialised in anti-trust law.

DR MEHDI JAVANBAKHT

Director

Optimax Access Ltd.

DR MEHDI JAVANBAKHT

Director

Mehdi holds a PhD in Health Economics and has over 16 years of experience in the Health Technology Assessment (HTA) field. He has a strong commercial sense and in-depth knowledge of modelling. He used to work as an Evidence Review Group (ERG) member for NICE. Mehdi has built over 120 health economic evaluation models from scratch for different diseases (Cancer, diabetes, cardiovascular diseases, Ophthalmology, …) and has published over 130 papers in peer-reviewed journals.

Apply to speak

EXHIBIT & SPONSOR